A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Thomas Jefferson University

Status and phase: Active, not recruiting; Phase 1

Conditions: Resectable Pancreatic Ductal Adenocarcinoma; Stage IA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage I Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage 0 Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8

Treatments: Drug: Pyrvinium Pamoate

Study type: Interventional

Funder types: Other

Identifiers

NCT05055323

JT 14689 (Other Identifier)

20F.041

Details and patient eligibility

About

This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.

Full description

PRIMARY OBJECTIVE:

I. To determine the safety and tolerability of pyrvinium pamoate (PP), dosed orally, in patients with pancreatic ductal adenocarcinoma (PDAC) that are surgical candidates.

SECONDARY OBJECTIVE:

I. Assessment of PP's pharmacokinetic and pharmacodynamic (PK/PD) profile and bioavailability in humans.

OUTLINE: This is a dose-escalation study.

Patients receive pyrvinium pamoate orally (PO) once daily (QD) for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.

After completion of study treatment, patients are followed up for 30 days and then every week for up to 4 weeks.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) suspected preoperatively who are deemed to be surgical candidates by the Thomas Jefferson University surgery department. Patients will be assessed by the pancreatic surgeons in the pancreatic surgery clinic, and if they are found to have resectable disease, they can be considered for this study

• Patients must not be on neoadjuvant therapy, or have received their last neoadjuvant treatment greater than or equal to within three weeks of starting PP therapy

• Provide signed and dated informed consent form

• Willing to comply with all study procedures and be available for the duration of the study

• Patients must have an estimated life expectancy of > 3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• All patients regardless of age or gender must agree to observe proper contraceptive methods as to avoid becoming pregnant or causing pregnancy for the duration of the study (30 days after last dose of drug)

  • Males will practice safe sex methods (i.e. condoms)
  • Women of child bearing potential will practice safe sex methods (i.e. condoms, birth control), if a female on the study is of child-bearing age, they will have to take a urine human chorionic gonadotropin (HCG) (pregnancy) test prior to enrolling on the study

Exclusion criteria

• Patients with ongoing anticancer therapies, or those who will have received an anticancer therapeutic <3 weeks prior to the first dose of PP

• Any condition that precludes pancreatic surgical resection at the time of the study

• Pregnancy or currently breastfeeding

• Known allergic reactions to components of the study product(s): pyrvinium pamoate/ pyrvinium embonate (Molevac)

• Patients with chronic bowel conditions (such as inflammatory bowel disease (IBD))

• Kidney function impairment (serum creatine > 1.5 x ULN or creatine clearance </= 60 ml/1.73m^2 fr patients with creatine levels > 1.5 x ULN).

• Patients with liver function impairment: Alkaline phosphatase, ALT and AST above three folds the normal limit (see normal ranges); Total Bilirubin level > 3mg/dl; Albumin < 3g/dl

  * Alkaline phosphatase:

  • 0-9 years (yr): 83-280 IU/L at 37 degrees Celsius
  • 10-14 yr: 91-400
  • 15-17 yr: 37-240
  • 18-49 yr: 29-92
  • 50-74 yr: 25-120
  • 75-97 yr: 29-160
  • 98-99 yr: 29-120
  • > 99 yr: 29-160

• Patients with liver function impairment outside of the below ranges

  * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]):

  ** Male (M): 1-45 IU/L at 37 degrees Celsius

  ** Female (F): 1-30

• Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]):

  • M: 7-42 IU/L at 37 degrees Celsius
  • F: 7-35

• Patients with liver function impairment outside of the below ranges

  * Albumin:

  • 0-1 yr: 2.6-4.4
  • 1-15 yr: 3.0-4.7
  • 16-99 yr: 3.2-4.9

• Patients with liver function impairment outside of the below ranges

  * Bilirubin, total:

  ** 0.1-0.9 mg/dL

• Patients with liver function impairment outside of the below ranges * Protein, total:

  • 0-1 yr: 4.6-7.2 g/dL
  • 1-15 yr: 5.7-8.2
  • 16-99 yr: 6.0-8.5

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Treatment (pyrvinium pamoate)

Experimental group

Description:

Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.

Treatment:

Drug: Pyrvinium Pamoate